Digital Health Investment Weekly Report [Issue 177] Files IPO Prospectus
Eight Sleep
Sleep Health Service Provider
Iantrek
Ophthalmic Medical Device Developer
Citizen Health
Artificial Intelligence Consumer Health Platform
01 Global Digital Health Investment and Financing Overview
Sleep Wellness Provider Eight Sleep Secures $100 Million in Funding
On August 19, sleep wellness service provider Eight Sleep secured $100 million in funding, with participation from institutions such as HSG and Valor Equity Partners, along with notable figures from the sports world including Charles Leclerc (Ferrari F1 driver) and Zak Brown (McLaren F1 CEO). The funds will be used to accelerate the company’s vision of transforming its bed into an AI-driven sleep optimization and preventive health device.
Hyperspectral Imaging Product Manufacturer Synlumin Conuninex Raises 400 Million Yuan in Series A Funding
On August 13, Synlumin Conuninex (Shanghai) Enterprise Development Co., Ltd., a producer of hyperspectral imaging products, secured 400 million yuan in its Series A round of financing. The round was led by its angel investor Shanghai United Investment, with participation from Fuhua Technology, Gaoyuan Capital, and other local state-owned enterprises and funds. Founding shareholder Gaowei Technology, along with existing investors Guanghe Hao and Weber Investment, among others, continued to increase their stakes. The proceeds from this round will primarily be used for research and development as well as productization in the fields of communications and optical processing.
Ophthalmic Medical Device Developer Iantrek Secures $42 Million in Series C Funding
On August 20, ophthalmic medical device developer Iantrek secured $42 million in Series C funding, led by U.S. Venture Partners (USVP), with participation from aMoon Fund and follow-on investments from existing investors such as Visionary Ventures. The funds will primarily be used to launch AlloFlo™ Uveo in the U.S. market, a first-of-its-kind surgical solution targeting the uveoscleral pathway, while also driving broader product line expansion.
Healthcare Service Provider Citizen Health Secures $30 Million in Series A Funding
On August 14, healthcare service provider Citizen Health secured $30 million in Series A funding, led by 8VC with participation from Transformation Capital and Headline. Citizen Health empowers patients to take control of their care and contribute to the healthcare field's richest research-grade datasets by integrating artificial intelligence, community, and longitudinal data.
Suzhou Yixi Biotechnology Co., Ltd., a solutions provider in the field of gut microbiota, secures nearly 200 million yuan in Series A financing
On August 20, Suzhou Yixi Biotechnology Co., Ltd., a solution provider in the field of gut microbiota, secured nearly 200 million yuan in its Series A round of financing. The round was led by Huangshan Industrial Investment Group, with participation from Huangshan Gongying Yixi Equity Investment Fund and social capital. The funds will primarily be used to support the construction of the world's largest HMOs monomer factory by Suzhou Yixi Biotechnology Co., Ltd.
Dr. Mayson Secures Nearly 200 Million RMB in Financing
On August 18, Dr. Mayson, a provider of medical artificial intelligence solutions, secured nearly 200 million RMB in funding, led by Shanghai Science and Technology Innovation Fund and CDH Investments, with continued support from Qiming Venture Partners and participation from Changning Capital through its Hongqiao Ruizhi Investment Platform. The company focuses on applying AI technology to address clinical pain points, and its AI product portfolio has covered over 1,200 tiered hospitals, more than 70% of which are tertiary hospitals.
Insulin Patch Pump Developer Luna Diabetes Secures $23.6 Million in Series A Funding
On August 19, Luna Diabetes, a developer of insulin patch pumps, secured $23.6 million in Series A funding led by Vensana Capital, with participation from the Swiss Diabetes Risk Investment Fund, Ascensia Diabetes Care, and others. The funds will be used to advance its automated insulin delivery solution designed for insulin pen users and to accelerate the development of Luna, the world's smallest insulin patch pump.
Rapid Diagnostic Product Developer FanZhi Medicine Secures 100 Million Yuan in D+ Round Financing
On August 21, Fast Diagnosis Product Developer FanZhi Medicine Secures RMB 100 Million in D+ Round Financing from Investors Including RayVenture and Jingchuang Investment. The funds will be used to promote the application of AI technology in the field of rapid disease diagnosis, accelerate the R&D iteration of AI-driven rapid testing instruments and multi-test diagnostic reagents, enhance the smart diagnostic product portfolio, and expedite the international registration of medical devices.
Synthetic Biology Research Company MicroFar Biotech Secures Nearly RMB 100 Million in Pre-A Funding
On August 19, Weiyuan Bio, a synthetic biology research company, secured nearly RMB 100 million in Pre-A funding, led by Rongtuo Capital and followed by Daotong Investment. Seed round shareholders, Dajing Venture Capital and Zhenshi Capital, continued to firmly increase their investments. This round of financing will be used to strengthen the AI-driven intelligent technology platform, accelerate the construction of key fermentation production pilot bases, and lay a solid foundation for large-scale industrialization, creating a world-leading green biomanufacturing engine.
Medical AI-native operating system developer Convoke secures $8.6 million in seed funding
On August 20, Convoke, a developer of medical artificial intelligence-native operating systems, secured $8.6 million in seed funding led by Kleiner Perkins and Dimension Capital, with participation from ACME, Comma Capital, Liquid2, and others. The funds will support the development of Convoke's AI operating system, a software tool that provides biopharmaceutical companies with unified internal and external data, codifies decision-making logic, and generates critical deliverables throughout the drug lifecycle.
Kaituo Biotech Collaborates with 3D Medicines to Advance the Industrial Application of AI+RNA and tLNP Technologies
On August 20, Cytio Biotech and 3D Medicines Inc. entered into a collaboration to advance the industrial application of AI+RNA and tLNP technologies in the field of cancer immunotherapy by combining their respective strengths. 3D Medicines Inc. has established an mRNA technology platform and an LNP delivery system platform with global proprietary intellectual property rights, which can support extensive antigen multi-omics analysis and the selection of optimal tumor antigens. The company also owns an AI-enhanced LNP delivery technology platform with independent intellectual property rights, capable of screening thousands of compounds through AI algorithms to ultimately synthesize various LNP products that cover different delivery scenarios.
XtalPi Collaborates with Dong-A ST to Develop New Drugs in Immunology and Inflammation
On August 20, XtalPi partnered with Korea's Dong-A ST to jointly develop innovative therapies targeting immunological and inflammatory diseases. The collaboration leverages XtalPi’s AI + robotics R&D platform, driven by quantum physics, artificial intelligence (AI), and robotic experimentation. Both companies will work together to identify targets and design and develop novel drug candidates with the potential to be either first-in-class or best-in-class.
Valkit.ai Collaborates with Life Science Consulting to Expand Global Reach of Second-Generation Digital Validation Platform
On August 19, Valkit.ai partnered with Life Science Consulting to leverage the latter's extensive client network in the global pharmaceutical industry and expand the global reach of Valkit.ai’s second-generation digital validation platform. This collaboration will combine Valkit.ai's advanced technical support with Life Science Consulting’s expertise and client base in the life sciences field, promoting the application of the Valkit.ai platform in international markets and offering pharmaceutical companies more efficient validation processes.
Mindler Acquires NHS Online Mental Health Service Provider Ieso Digital Health UK
On August 20, digital therapeutics company Mindler acquired Ieso Digital Health UK, an online mental health service provider. This acquisition allows Mindler to gain existing contracts between Ieso and the National Health Service (NHS) systems in England and Scotland. Mindler aims to meet the growing demand for mental health services in the UK, especially given the relatively high vacancy rate of doctor positions within NHS mental health services.
Autism Online Treatment Platform RethinkCare Acquires Joshin
On August 19, RethinkCare, an online treatment platform for autism, acquired Joshin, a provider of disability and neurodiversity support services. The RethinkCare platform offers solutions for career resilience, parental success, and personal well-being, including evidence-based behavioral and mental health skills training. This acquisition will expand RethinkCare's platform capabilities, providing families and employers with a broader range of personalized care pathways, supplier matching, and expert guidance.
Artery Network/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/Fierce Health, etc.
Share
Like
Click to view